5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Cited by (1,367)

Items 101–200 of 1,367

1. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
   Komal L. Jhaveri, Elgene Lim, Rinath M. Jeselsohn, Cynthia X. Ma, Erika Paige Hamilton, Cynthia R. C. Osborne, Manali Ajay Bhave, Peter Andrew Kaufman, Joseph Thaddeus Beck, Luís Manso et al. · 2024 · Journal of Clinical Oncology
2. Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches
   Alessia Pellerino, Priscilla Kaliopi Brastianos, Roberta Rudà, Riccardo Soffietti · 2021 · Cancers
3. Clinical implication of low estrogen receptor (ER-low) expression in breast cancer
   Tomás Reinert, Fanny Gueselha de Almeida Cascelli, Cristiano Augusto Andrade de Resende, Aline Coelho Gonçalves, Vania Sanchez Prette Godo, Carlos H. Barrios · 2022 · Frontiers in Endocrinology
4. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
   Min Huang, Amin Haiderali, Grace E. Fox, Andrew M. Frederickson, Javier Cortés, Peter Andreas Fasching, Joyce O’Shaughnessy · 2022 · PharmacoEconomics
5. Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies
   Florian Moik, Cihan Ay · 2022 · Thrombosis Research
6. Clinical Use of PET/MR in Oncology: An Update
   Robert Seifert, David Kersting, Christoph Rischpler, Marcel Klaus Opitz, Julian Kirchner, Kim Magaly Pabst, Ilektra Antonia Mavroeidi, Christina Laschinsky, Johannes Stefan Grueneisen, Benedikt M. Schaarschmidt et al. · 2021 · Seminars in Nuclear Medicine
7. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
   Joyce O’Shaughnessy, Adam Brufsky, Hope S. Rugo, Sara M. Tolaney, Kevin Punie, Sagar D. Sardesai, Erika Paige Hamilton, Delphine Loirat, Tiffany A. Traina, Roberto Antonio Leon-Ferre et al. · 2022 · Breast Cancer Research and Treatment
8. Early-Onset Cancers in Adults: A Review of Epidemiology, Supportive Care Needs and Future Research Priorities
   Ashleigh C. Hamilton, David W Donnelly, Deirdre Fitzpatrick, Helen G. Coleman · 2022 · Cancers
9. Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
   Komal L. Jhaveri, Frederik Marmé · 2023 · Cancer Treatment Reviews
10. Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography
    Daniela E. Oprea‐Lager, Matthijs C. F. Cysouw, Ronald Boellaard, Christophe M. Deroose, Lioe‐Fee de Geus‐Oei, Egesta Lopci, Luc M. Bidaut, Ken Herrmann, Laure S Fournier, Tobias Bäuerle et al. · 2021 · Frontiers in Oncology
11. Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
    Jun Ma, Jack Junjie Chan, Ching Han Toh, Yoon Sim Yap · 2023 · npj Breast Cancer
12. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing 18F-FDG PET/CT with Conventional CT
    M. Vogsen, F. Harbo, N. Jakobsen, H. J. Nissen, S. E. Dahlsgaard-Wallenius, O. Gerke, J. D. Jensen, J. Asmussen, A. Jylling, P. Braad et al. · 2022 · Journal of Nuclear Medicine
13. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
    Valentina Guarneri, Fara Brasó‐Maristany, Maria Vittoria Dieci, Gaia Griguolo, Laia Paré, Mercedes Marín‐Aguilera, Federica Miglietta, Michele Bottosso, Carlo Alberto Giorgi, Paula Blasco et al. · 2022 · EBioMedicine
14. TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
    Isabel Grote, Stephan Bartels, Leonie Donata Kandt, L Bollmann, Henriette Christgen, Malte Gronewold, Mieke Raap, Ulrich Lehmann, Oleg Gluz, Ulrike Anneliese Nitz et al. · 2021 · Cancer Medicine
15. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial
    Nadia Harbeck, Peter Andreas Fasching, Rachel Wuerstlein, Tom Degenhardt, Diana Lüftner, Ronald Ernest Kates, Johannes Schumacher, Philip Räth, Oliver Hoffmann, Ralf Lorenz et al. · 2023 · Annals of Oncology
16. Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
    Elisabetta Munzone, Eleonora Pagan, Vincenzo Bagnardi, Emilia Montagna, Giuseppe Cancello, Silvia Dellapasqua, Monica Iorfida, M. Mazza, Marco Angelo Colleoni · 2021 · ESMO Open
17. Review of imaging techniques for evaluating morphological and functional responses to the treatment of bone metastases in prostate and breast cancer
    J. Orcajo-Rincón, J. Muñoz-Langa, J. M. Sepúlveda-Sánchez, G. Fernández-Pérez, M. Martínez, E. Noriega-Álvarez, S. Sanz-Viedma, J. Vilanova, A. Luna · 2022 · Clinical and Translational Oncology
18. Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
    Vincenzo Di Lauro, Giacomo Barchiesi, Federica Martorana, G Zucchini, Margherita Muratore, Caterina Fontanella, Grazia Arpino, Lucia Del Mastro, Mario Giuliano, Fabio Puglisi et al. · 2022 · ESMO Open
19. Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
    Iris Garrido‐Cano, Anna Adam‐Artigues, Ana Lameirinhas, Juan F. Blandez, Vicente Candela‐Noguera, Ana M. Lluch, Begoña Bermejo, Félix Sancenón, Juan Miguel Cejalvo, Ramón Martínez‐Máñez et al. · 2023 · ACS Applied Materials & Interfaces
20. Predictive and prognostic biomarkers of bone metastasis in breast cancer: current status and future directions
    Shenkangle Wang, Wenxin Wu, Xixi Lin, Kevin Matthew Zhang, Qingliang Wu, Mingpeng Luo, Jichun Zhou · 2023 · Cell & Bioscience
21. Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer
    Alejandra Estepa‐Fernández, Alba García‐Fernández, Araceli Lérida‐Viso, Juan F. Blandez, Irene Galiana, Félix Sancenón, Mar Orzáez, Ramón Martínez‐Máñez · 2022 · Pharmacological Research
22. BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs?
    Peter Christian Dubsky, Christian Jackisch, Seock‐Ah Im, Kelly K. Hunt, Chien‐Feng Li, Sheila Unger, Shani Paluch–Shimon · 2024 · npj Breast Cancer
23. Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
    Melinda L. Telli, Sara M. Tolaney, Geoffrey Ira Shapiro, Mark Ross Middleton, Simon Lord, Hendrik‐Tobias Arkenau, Andrew N.J. Tutt, Vandana Gupta Abramson, Emma Jane Dean, Tufia C. Haddad et al. · 2022 · npj Breast Cancer
24. Prognostic Significance of Low HER2 Expression in Patients With Early Hormone Receptor Positive Breast Cancer
    George Douganiotis, Loukas Kontovinis, Efrosini Markopoulou · 2022 · Cancer Diagnosis & Prognosis
25. Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges
    Hiu Ting Chan, Yoon Ming Chin, Siew‐Kee Low · 2022 · Cancers
26. Gut microbiome causal impacts on the prognosis of breast cancer: a Mendelian randomization study
    Weimin Hong, Guoxin Huang, Danhong Wang, Yadan Xu, Jie Qiu, Bin Pei, Da Qian, Xuli Meng · 2023 · BMC Genomics
27. Adjuvant Breast Cancer Treatments Cardiotoxicity and Modern Methods of Detection and Prevention of Cardiac Complications
    Agata Bikiewicz, Maciej Banach, Stephan von Haehling, Marek Maciejewski, Agata Magdalena Bielecka-Dabrowa · 2021 · ESC Heart Failure
28. Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
    Anastasia Alataki, Mitch Dowsett · 2022 · Endocrine Related Cancer
29. Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial
    Leiping Wang, Jun Cao, Chunlei Li, Xiaodong Wang, Yannan Zhao, Ting Li, Yiqun Du, Zhonghua Tao, Wenxia Peng, Biyun Wang et al. · 2021 · Investigational New Drugs
30. Depression, anxiety and stress among metastatic breast cancer patients on chemotherapy in China
    Yi-Qiang Guo, Qing-Mei Ju, Miaoning You, Yang Liu, Azlina Yusuf, Lean Keng Soon · 2023 · BMC Nursing
31. Paraoxonase-2 is upregulated in triple negative breast cancer and contributes to tumor progression and chemoresistance
    Roberto Campagna, Valentina Pozzi, Sara Giorgini, Doriana Morichetti, Gaia Goteri, Davide Sartini, Emma Nicol Serritelli, Monica Emanuelli · 2023 · Human Cell
32. Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer
    Komal L. Jhaveri, Melissa Kate Accordino, Philippe Lucien Bedard, Andrès M.R. Cervantes, Valentina Gambardella, Erika Paige Hamilton, Antoîne Italiano, Kevin M. Kalinsky, Ian E. Krop, Mafalda Oliveira et al. · 2024 · Journal of Clinical Oncology
33. Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
    Nicholas C. Turner, Cristina Saura, Philippe Georges Aftimos, Evelyn van den Tweel, M. Oesterholt, N.P. Koper, Marco Angelo Colleoni, Emilie Kaczmarek, Kevin Punie, Xinni Song et al. · 2024 · Journal of Clinical Oncology
34. Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators
    Ying Fan, Tao Sun, Zhimin Shao, Qingyuan Zhang, Quchang Ouyang, Zhongsheng Tong, Shusen Wang, Yang Luo, Yuee Teng, Xiaojia Wang et al. · 2021 · JAMA Oncology
35. Aiming at a Tailored Cure for ERBB2 -Positive Metastatic Breast Cancer
    Paolo Tarantino, Giuseppe Curigliano, Heather A. Parsons, NU Lin, Ian E. Krop, Elizabeth A. Mittendorf, Adrienne Gropper Waks, Eric P. Winer, Sara M. Tolaney · 2022 · JAMA Oncology
36. Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
    Mattea Reinisch, Simona Bruzas, Jennifer Spoenlein, Satyendra S. Shenoy, Alexander Traut, Hakima Harrach, Ouafaa Chiari, E. Cremer, Beyhan Ataseven, Lars Gubelt et al. · 2023 · Therapeutic Advances in Medical Oncology
37. Understanding Patient Preferences Regarding the Important Determinants of Breast Cancer Treatment: A Narrative Scoping Review
    Hui Yee Yeo, Ai Ch’i Liew, Suz Jack Chan, Mudassir Anwar, Catherine HyeWon Han, Carlo A. Marra · 2023 · Patient Preference and Adherence
38. Margetuximab for the treatment of HER2-positive metastatic breast cancer
    Paolo Tarantino, Stefania Morganti, Jacopo Uliano, Federica Giugliano, Edoardo Crimini, Giuseppe Curigliano · 2020 · Expert Opinion on Biological Therapy
39. Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer
    Mónica Cejuela Solís, Andrea Vethencourt, Sònia Pernas · 2022 · Current Oncology Reports
40. Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology
    Carmen Criscitiello, Elena Guerini‐Rocco, Giulia Viale, Caterina Fumagalli, Elham Sajjadi, Konstantinos Venetis, Roberto Piciotti, Marco Invernizzi, Umberto Malapelle, Nicola Fusco · 2021 · Anti-Cancer Agents in Medicinal Chemistry
41. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
    Shanade Dunn, Cath Eberlein, Jason Yu, Albert Gris‐Oliver, Swee Hoe Ong, Urs Yelland, Natalie Cureton, Anna Dominika Staniszewska, Robert K. McEwen, Millie Fox et al. · 2022 · Oncogene
42. Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges
    Isha Bansal, Amit Kumar Pandey, Munindra Ruwali · 2023 · Frontiers in Pharmacology
43. A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models
    Mika Kato Kaneko, Hiroyuki Suzuki, Tomokazu Ohishi, Takuro Nakamura, Tomohiro Tanaka, Yukinari Kato · 2024 · International Journal of Molecular Sciences
44. Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer
    Christen A. Khella, Gaurav A. Mehta, Rushabh N. Mehta, Michael L. Gatza · 2021 · Journal of Personalized Medicine
45. Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
    Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jérusalem et al. · 2021 · Cancers
46. Unveiling the mechanism of action behind the anti-cancer properties of cannabinoids in ER+ breast cancer cells: Impact on aromatase and steroid receptors
    Cristina Amaral, Fabien Marc Trouille, Cristina Ferreira Almeida, Georgina Correia‐da‐Silva, Natércia A. A. Teixeira · 2021 · The Journal of Steroid Biochemistry and Molecular Biology
47. Targeting the Tumor Microenvironment in Breast Cancer: Prognostic and Predictive Significance and Therapeutic Opportunities
    Maria A Dominguez-Cejudo, Ana Gil-Torralvo, Mónica Cejuela Solís, Sonia Molina‐Pinelo, Javier Salvador Bofill · 2023 · International Journal of Molecular Sciences
48. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
    Patrick Neven, Hope S. Rugo, Sara M. Tolaney, Hiroji Iwata, Masakazu Toi, Matthew Philip Goetz, Peter Andrew Kaufman, Yi Lu, Nadine Haddad, Karla C. Hurt et al. · 2021 · Breast Cancer Research
49. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021
    Marc Thill, Michael Friedrich, Cornelia Kolberg‐Liedtke, Ute‐Susann Albert, Maggie Banys‐Paluchowski, Ingo Bauerfeind, Jens‐Uwe Blohmer, Wilfried Budach, Peter Dall, Eva Maria Fallenberg et al. · 2021 · Breast Care
50. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023
    Marc Thill, Cornelia Kolberg‐Liedtke, Ute‐Susann Albert, Malgorzata Joanna Banys-Paluchowski, Ingo Bauerfeind, Jens‐Uwe Blohmer, Wilfried Budach, Peter Dall, Nina Ditsch, Eva Maria Fallenberg et al. · 2023 · Breast Care
51. BRCA Mutations and Fertility Preservation
    Joana Dias Nunes, Isabelle Demeestere, Melody Devos · 2023 · International Journal of Molecular Sciences
52. DNA damage response in breast cancer and its significant role in guiding novel precise therapies
    Jiayi Li, Ziqi Jia, Dong Lin, Heng Cao, Yansong Huang, Hengyi Xu, Zhixuan Xie, Yiwen Jiang, Xiang Wang, Jiaqi Liu · 2024 · Biomarker Research
53. Updates in endocrine therapy for metastatic breast cancer
    Poorni M. Manohar, Nancy E. Davidson · 2021 · Cancer Biology and Medicine
54. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
    Aurelia Noske, Daniel‐Christoph Wagner, Kristina Schwamborn, Sebastian Foersch, Katja Steiger, Marion B. Kiechle, Dirk Oettler, Siranush Karapetyan, Alexander Hapfelmeier, Wilfried Roth et al. · 2021 · The Breast
55. “The use of bisphosphonates to treat skeletal complications in solid tumours”
    Stella D’Oronzo, Steven L. Wood, Janet Elizabeth Brown · 2021 · Bone
56. Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients
    Julien Corné, Fanny Le Du, Véronique Quillien, Florence Godey, Lucie Robert, Héloïse Bourien, Angélique Brunot, Laurence Crouzet, Christophe Perrin, Claudia Lefeuvre‐Plesse et al. · 2021 · Scientific Reports
57. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
    Doudou Li, Zhonghua Tao, Biyun Wang, Leiping Wang, Jun Cao, Xichun Hu, Jian Zhang · 2022 · npj Breast Cancer
58. Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
    Matteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, Silvia Mura, Sabino De Placido, Michelino De Laurentiis, Alessandra Fabi, Anita Rimanti, Andrea Michelotti, Mauro Mansutti et al. · 2023 · EClinicalMedicine
59. Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights
    Harsh Vardhan Batra, Jason Aboudi Mouabbi, Qingqing Ding, Ayşegül A. Şahin, Maria Gabriela Raso · 2023 · Cancers
60. The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer
    Krishnaswamy Kannan, Alagarsamy Srinivasan, Aarthi Kannan, Nawab Ali · 2025 · Cancers
61. Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair–Related Genes
    Luisina Ines Bruno, Alexis Ostinelli, Federico Waisberg, Diego Hernán Enrico, Carolina Ponce, Sergio Gabriel Rivero, Albano Blanco, Martín Zarbá, Martín Loza, Verónica Fabiano et al. · 2022 · JCO Precision Oncology
62. HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
    Laura A. Morsberger, Aparna Pallavajjala, Patty Long, Melanie Hardy, Rebecca Park, Rebecca Parish, Azin Nozari, Ying S. Zou · 2022 · Cancer Cell International
63. The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery
    Sofia Batalha, Sofia Cristóvão‐Ferreira, Catarina Brito · 2021 · Cancers
64. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
    Zsuzsanna Kahán, Miguel Gil‐Gil, Manuel Ruíz‐Borrego, Eva Carrasco, Eva Ciruelos, Montserrat Muñoz-Mateu, Begoña Bermejo, Mireia Margelí Vila, Antonio Antón, Maribel Casas et al. · 2021 · European Journal of Cancer
65. Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer
    Bruno de Paula, Rosalind Kieran, Samantha Shui Yuan Koh, Susanne Crocamo, Eliana S. F. W. Abdelhay, Daniel Muñoz‐Espín · 2023 · Molecular Cancer Therapeutics
66. HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
    Katarzyna Joanna Jerzak, Nathaniel Bouganim, Christine Brezden‐Masley, Scott J. Edwards, Karen A. Gelmon, Jan‐Willem Henning, John Frederick Hilton, Sandeep R. Sehdev · 2023 · Current Oncology
67. PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
    Ju Won Kim, Ah Reum Lim, Ji Young You, Jung‐Hyun Lee, Sung Eun Song, Nam Kwon Lee, Seung Pil Jung, Kyu Ran Cho, Chul Yong Kim, Kyong Hwa Park · 2022 · Cancer Research and Treatment
68. Management of Brain and Leptomeningeal Metastases from Breast Cancer
    Alessia Pellerino, Valeria Internò, Francesca Mo, Federica Franchino, Riccardo Soffietti, Roberta Rudà · 2020 · International Journal of Molecular Sciences
69. Why is appropriate healthcare inaccessible for many European breast cancer patients? – The EBCC 12 manifesto
    Fátima Cardoso, Fiona A. MacNeill, Frederique Madeleine Penault-Llorca, Alexandru E. Eniu, Francesco Sardanelli, Elizabeth Bergsten Nordström, Philip M. Poortmans · 2021 · The Breast
70. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
    Aditya Bardia, Javier Cortés, Sara Alsterlind Hurvitz, Suzette Delaloge, Hiroji Iwata, Zhi‐Ming Shao, Dheepak Kanagavel, Patrick Cohen, Qianying Liu, Sylvaine Cartot‐Cotton et al. · 2022 · Therapeutic Advances in Medical Oncology
71. Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside
    Icro Meattini, Lorenzo Livi, Nicla Lorito, Carlotta Becherini, Marina Bacci, Luca Visani, Alessandra Fozza, Liliana Belgioia, Mauro Loi, Monica Mangoni et al. · 2022 · Cancer Treatment Reviews
72. Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives
    Christina Panagiotis Malainou, Nikolina Stachika, Aikaterini Konstantina Damianou, Aristotelis Anastopoulos, Ioanna Ploumaki, Efthymios Triantafyllou, Konstantinos Drougkas, Georgia Gomatou, Elias Alexandros Kotteas · 2023 · Current Oncology
73. Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines
    D. Groheux, Sofia C. Vaz, P. Poortmans, Ritse M. Mann, G. Ulaner, Gary J. R. Cook, Elif Hindié, J. P. Pilkington Woll, Heather Jacene, I. T. Rubio et al. · 2024 · Breast
74. Does Breast Cancer Increasingly Affect Younger Women?
    Katarzyna Konat-Bąska, Rafał Matkowski, Jerzy Błaszczyk · 2020 · International Journal of Environmental Research and Public Health
75. Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice
    Marcus Schmidt, Anne-Sophie Heimes · 2021 · Cancers
76. Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
    Christine E. Simmons, Daniel Rayson, Anil Abraham Joy, Jan‐Willem Henning, Julie Lemieux, Heather L. McArthur, Paul B. Card, Rebecca Alexandra Dent, Christine Brezden‐Masley · 2022 · Therapeutic Advances in Medical Oncology
77. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA -mutated breast cancer
    José Alejandro Pérez Fidalgo, Carmen Criscitiello, Eva Carrasco, Meredith M. Regan, Angelo Di Leo, Karin Ribi, Virginie Sarah Adam, Philippe Lucien Bedard · 2022 · Future Oncology
78. HPV-Associated Breast Cancer: Myth or Fact?
    Erik Kúdela, Eva Kúdelová, Erik Kozubík · 2022 · Pathogens
79. Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer
    Mathilde Louise Gehrchen, Tobias Berg, Rasmus Garly, Maj‐Britt Jensen, Saskia Eßer-Naumann, Jeanette Dupont Rønlev, Hanne Melgaard Nielsen, Ann Søegaard Knoop, Iben Kümler · 2024 · BJC Reports
80. Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies
    Quchang Ouyang, Jordi Ahnert Rodon, Yan Liang, Xinhong Wu, Qun Li, Lihua Song, Min Yan, Zhongsheng Tong, Yunpeng Liu, Zev A. Wainberg et al. · 2025 · Journal of Hematology & Oncology
81. Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting
    Elena Sultova, Christoph Benedikt Westphalen, Andreas Jung, Joerg Kumbrink, Thomas Kirchner, Doris Cooper Mayr, Martina Rudelius, Steffen Ormanns, Volker Heinemann, Klaus Hans Metzeler et al. · 2021 · Diagnostics
82. Benefits and harms of implementing [18F]FDG-PET/CT for diagnosing recurrent breast cancer: a prospective clinical study
    Marianne Vogsen, Jeanette Dupont Jensen, Oke Gerke, Anne Marie Bak Jylling, Jon Thor Asmussen, Ivar Yannick Christensen, Poul‐Erik Braad, Peter Thye‐Rønn, Katrine Lydolph Søe, Marianne Ewertz et al. · 2021 · EJNMMI Research
83. Whole-body MRI in oncology: can a single anatomic T2 Dixon sequence replace the combination of T1 and STIR sequences to detect skeletal metastasis and myeloma?
    Ophélye Chiabai, Sandy Van Nieuwenhove, Marie‐Christiane Vekemans, Bertrand F. TOMBAL, Frank Peeters, Joris Wuts, Perrine Triqueneaux, Patrick Omoumi, Thomas Kirchgesner, Nicolas Michoux et al. · 2022 · European Radiology
84. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
    Binghe Xu, Tao Sun, Yanxia Shi, Jiuwei Cui, Yongmei Yin, Quchang Ouyang, Qiang Liu, Qingyuan Zhang, Yiding Chen, Shouman Wang et al. · 2022 · Breast Cancer Research and Treatment
85. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
    Kreina Sharela Vega Cano, David Humberto Marmolejo Castañeda, Santiago Escrivá-de-Romaní, Cristina Saura · 2022 · Cancers
86. International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients
    Kelly M. de Ligt, Belle Hadewijch de Rooij, Elham Hedayati, Maria Margarete Karsten, Veerle R. Smaardijk, Mirjam Velting, Christobel Mary Saunders, Luzia Travado, Fátima Cardoso, Elizabeth Lopez et al. · 2023 · Breast Cancer Research and Treatment
87. Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
    Sara M. Tolaney, Shom Goel, Jorge Carlos Nadal, Hannelore G Denys, Manuel Ruíz Borrego, Lacey M. Litchfield, Jiangang Liu, Adams K. Appiah, Yanyun Chen, Fabrice André · 2023 · Clinical Cancer Research
88. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study
    B. Pistilli, Komal L. Jhaveri, Seock‐Ah Im, Sònia Pernas, Michelino De Laurentiis, S. Wang, N.Martínez Jañez, G. Borges, D.W. Cescon, Masaya Hattori et al. · 2025 · Annals of Oncology
89. Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
    R. Dent, Z. Shao, P. Schmid, Javier Cortés, D.W. Cescon, S. Saji, K.H. Jung, Thomas Bachelot, S. Wang, E.M. Ramírez et al. · 2026 · Annals of Oncology
90. Discovery of a multi-target compound for estrogen receptor-positive (ER+) breast cancer: Involvement of aromatase and ERs
    Cristina Ferreira Almeida, Natércia A. A. Teixeira, Ana L. Novo de Oliveira, Tiago Vieira Augusto, Georgina Correia‐da‐Silva, Maria João Ramos, Pedro Alexandrino Fernandes, Cristina Amaral · 2020 · Biochimie
91. Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box
    Paolo Tarantino, Aleix Prat, Javier Cortés, Fátima Cardoso, Giuseppe Curigliano · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
92. Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT
    Mohammad Naghavi‐Behzad, Marianne Vogsen, Rasmus Mølgård Vester, Maiken Madsen Bjerregaard Olsen, Hjalte Rasmus Oltmann, Poul‐Erik Braad, Jon Thor Asmussen, Oke Gerke, Werner Vach, Kristian Kidholm et al. · 2022 · British Journal of Cancer
93. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
    Benedetta Pellegrino, Luigi Cavanna, Daniela Boggiani, Claudio Zamagni, Antonio Frassoldati, Alessio Schirone, Alessia Caldara, Andrea Rocca, Stefania Gori, Federico Piacentini et al. · 2021 · ESMO Open
94. An Integrated Care Approach to Improve Well-Being in Breast Cancer Patients
    Alessandra Fabi, Alessandro Rossi, Edoardo Mocini, Ludovica Cardinali, Valério Bonavolontá, Cristina Cenci, Stefano Magno, Vittoria Barberi, Antimo Moretti, Zein Mersini Besharat et al. · 2024 · Current Oncology Reports
95. Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease
    Gavin Paul Dowling, Stephen Keelan, Nicola S. Cosgrove, Gordon Richard Daly, Katie Giblin, Sinéad Toomey, Bryan T. Hennessy, Arnold D. K. Hill · 2024 · Breast Cancer Research and Treatment
96. Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
    Élia Cipriano, Alexandra Mesquita · 2021 · Breast Cancer Basic and Clinical Research
97. Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women
    Valentino Martelli, Maria Maddalena Latocca, Tommaso Ruelle, Marta Perachino, Luca Arecco, Kristi Beshiri, Maria Grazia Razeti, Marco Tagliamento, Maurizio Cosso, Piero Fregatti et al. · 2021 · Breast Cancer Targets and Therapy
98. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer
    Josh John Carlson · 2022 · The American Journal of Managed Care
99. Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
    Qianying Zuo, Ayca Nazli Mogol, Yu-Jeh Liu, Ashlie Santaliz Casiano, Christine Chien, Jenny M. Drnevich, Ozan Berk Imir, Eylem Kulkoyluoglu‐Cotul, Nicole Hwajin Park, David J. Shapiro et al. · 2022 · Molecular Cancer Research
100. Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
     Julie M. Lebert, Evan J. Lilly · 2022 · Current Oncology